Literature DB >> 6762301

Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

W Kirch, H Kohler, T Axthelm.   

Abstract

Eight patients with terminal renal failure (GFR less than 5 ml/min) received guanfacine intravenously or orally at the beginning of a haemodialysis session lasting 5 hours. After intravenous administration the elimination rate constant of the unchanged drug was calculated to be 0.59 h-1, corresponding to an elimination half-life of about 12 h, which is similar to the values of patients with normal renal function. Following oral ingestion, only 2.4% of the guanfacine dose administered were extracted unchanged in the dialysate during the haemodialysis period. The clearance by dialysis was 53 ml/min for guanfacine, which represents about 15% of the total clearance of guanfacine reported in the literature. The low dialysis clearance of guanfacine is consistent with the high rate of biotransformation of the drug and its binding to red blood cells and plasma proteins. Thus guanfacine may be dosed independently of haemodialysis treatment periods.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6762301     DOI: 10.1007/BF03189630

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Long-term treatment of hypertension with guanfacine alone and in combination therapy.

Authors:  Y K Seedat
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

2.  Elimination of guanfacine in patients with normal and impaired renal function.

Authors:  W Kirch; H Köhler; W Braun
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

Review 3.  Pharmacokinetics and metabolism of guanfacine in man: a review.

Authors:  J R Kiechel
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

4.  Substituted phenylacetylguanidines: a new class of antihypertensive agents.

Authors:  J B Bream; H Lauener; C W Picard; G Scholtysik; T G White
Journal:  Arzneimittelforschung       Date:  1975-10

5.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

6.  Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine.

Authors:  W Kirch; A Distler
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-03

7.  Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.

Authors:  P Jerie; A Lasance
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-06

8.  The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

Authors:  W Kirch; H Köhler; W Braun; C von Gizycki
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

  8 in total
  3 in total

Review 1.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

Review 2.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

3.  Method development and validation of Guanfacine in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study.

Authors:  Suryanarayana Murthy Goparaju; Yadagiri Srinivasa Murthy Nandula; Chandrasekher Bannoth Kothapalli; B R Challa; Bahlul Z Awen
Journal:  J Pharm Anal       Date:  2013-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.